Curosurf (Poractant Alfa)

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product helps improve lung function and oxygenation, making it a critical treatment in neonatal care.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed and lack sufficient surfactant, a substance that keeps the air sacs open. By replenishing surfactant levels, Curosurf aids in improving lung function and facilitating better oxygenation. It is administered directly into the lungs via endotracheal tube, making it a targeted treatment for neonatal respiratory issues.

Curosurf works by replacing the natural surfactant in the lungs, which helps reduce surface tension and allows the air sacs to remain open. This can lead to improved breathing and oxygen levels in premature infants. The effects are typically observed shortly after administration, providing rapid relief from respiratory distress.

Curosurf should be administered by healthcare professionals experienced in neonatal care. It is important to follow proper handling and storage guidelines to maintain its efficacy. As with any medical treatment, monitoring for any adverse reactions is crucial. Always consult healthcare providers for specific precautions and contraindications.

Curosurf is generally used in a controlled medical environment, and interactions with other medications are not commonly reported. However, it is essential to inform healthcare providers about any other treatments the infant may be receiving to ensure safety and compatibility. Always follow medical advice regarding concurrent therapies.